פרופסור אלי מגן פרסומים מדעיים

מאמרים מדעיים

Refereed original articles in scientific journals 1. Leng Q, Bentwich Z, Magen E, Kalencovich A, Borkow G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS. 2002, 16: 519-529 (jR: 2/38, Q1, IF- 5.983, CI - 71) 2. Yosefy C, Khalamizer V, Viskoper JR, Iaina A, Manevich I, London D, Jafari J, Magen E, Wollman Y, Reisin L. Impaired nitric oxide production, brachial artery reactivity and fish oil in offspring of ischaemic heart disease patients. Br J Biomed Sci. 2003; 60(3):144-148. (jR: 16/26, Q3, IF – 1.179, CI - 3) 3. Yosefy C, Hay E, Ben-Barak A, Derazon H, Magen E, Reisin L, Scharf S. BiPAP ventilation as assistance for patients Currenting with respiratory distress in the department of emergency medicine. Am J Respir Med. 2003; 2(4):343-347. (jR: NA, Q -NA, IF-NA, CI – 13) 4. Yosefy C, Hay E, Nasri Y, Magen E, Reisin L. End tidal carbon dioxide as a predictor of the arterial PCO2 in the emergency department setting. Emerg Med J. 2004; 21(5):557-9. (jR: 8/11, Q3, IF – 0.681, CI - 58) 5. Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, Viskoper RJ. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol. 2004; 44(2):215-222. (jR: 34/71, Q2, IF - 1.576, CI –58) 6. Magen E, Viskoper R, Mishal J, Priluk R, Berezovsky A, Laszt A, London D, Yosefy C. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J. 2004 Dec; 6(12):742-746. (jR: 73/103 Q3, IF – 0.488, CI - 34) 7. Magen E, JR. Viskoper, J. Mishal, R. Priluk, D. London, C. Yosefy. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. Journal of Human Hypertension; 2005 (7), 667-673 (jR: 22/51, Q2, IF- 2.405 CI - 45) 8. Sthoeger Z, Neiman A, Elbirt D, Zinger H, Magen E, Burstein R, Eitan S, Abarbanel J, Mozes E. High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study. Am J Med Sci. 2006; 331(1):4-9. (jR: 41/103, Q2, IF- 1.355, CI - 40) 9. Magen E, Yosefy C, Viskoper RJ, Mishal J. Treatment of allergic rhinitis can improve blood pressure control. J Hum Hypertens. 2006; 20(11):888-893. (jR: 18/52, Q2, IF- 2.960, CI - 14) 10. Magen E, Mishal J, Schlesinger M. Sensitizations to allergens of TRUE test in 864 consecutive eczema patients in Israel. Contact Dermatitis. 2006; 55(6):370-371. (jR: 8/39, Q1, IF- 2.446, CI - 10) 11. Magen E, Mishal J, Schlesinger M, Scharf S. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter. 2007; 12(5):567-571. (jR: 23/50, Q2, IF - 2.423, CI - 38) 12. Mishal J, Embon A, Darawshe A, Kidon M, Magen E. Community acquired acute bacterial meningitis in children and adults: An 11-year survey in a community hospital in Israel. European Journal of Internal Medicine, 2008; 19(6):421-426. (jR: 70/107 Q3, IF- 1.045, CI - 8) 13. Zeldin Y, Weiler Z, Cohen A, Kalinin M, Schlesinger M, Kidon M, Magen E. Efficacy of nasal Staphylococcus aureus eradication by topical nasal mupirocin in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2008 Jun; 100 (6):608-611. (jR: 71/121, Q3, IF- 2.353; CI - 3) 14. Zeldin Y, Kidon MI, Magen E, Bibi H, Cohen A, Waisel Y, Kivity S. Impact of specific allergen sensitization on the prevalence of asthma in patients with allergic rhinitis from adjacent distinct geographic areas. Ann Allergy Asthma Immunol. 2008 Jul; 101(1):30-34. (jR: 71/121, Q3, IF- 2.353; CI - 10) 15. Vitkovsky Y, Kuznik B, Solpov A, Magen E. Status of platelet-lymphocyte aggregation in circulating blood of patients with type 1 diabetes with and without diabetic nephropathy. Isr Med Assoc J. 2008 Oct;10(10):691-694 (jR: 85/107, Q4, IF – 0.626, CI - 3) 16. Magen E, Mishal J, Paskin J, Glick Z, Zeldin Y, Viskoper R, Schlesinger M. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. Journal of Clinical hypertension. 2008; 10(9):677-683. *2021: (jR: 43/67, Q3, IF- 2.885, CI - 25) 17. Zeldin Y, Weiler Z, Magen E, Tiosano L, Kidon MI. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. Isr Med Assoc J. 2008; 10(12):869-872. (jR: 85/107, Q4, IF – 0.626, CI - 14) 18. Magen E, Agmon-Levin N, Elbirt D, Mishal J, Sthoeger Z. Eradication of helicobacter pylori infection can facilitate immune reconstitution in patients with HIV-1 infection. International Journal of Infectious diseases. 2010; 14(4):e322-e327. (jR: 31/58, Q3, IF- 2.529, CI - 6) 19. Weiler Z, Zeldin Y, Magen E, Zamir D, Kidon MI. Pulmonary function correlates with arterial stiffness in asthmatic patients. Respir Med. 2010; 104(2):197-203. (jR: 46/114, Q2, IF- 2.525, CI - 17) 20. Magen E, Feldman A, Cohen Z, Alon DB, Minz E, Chernyavsky A, Linov L, Mishal J, Schlezinger M, Sthoeger Z. Circulating endothelial progenitor cells, Th1/Th2/Th17-related cytokines, and endothelial dysfunction in resistant hypertension. Am J Med Sci. 2010 Feb; 339(2):117-22. (jR: 70/153, Q2, IF- 1.257, CI - 8) 21. Magen E, Feldman A, Cohen Z, Alon DB, Linov L, Mishal J, Schlezinger M. Potential link between C3a, C3b and endothelial progenitor cells in resistant hypertension. Am J Med Sci. 2010; 339(5):415-419. (jR: 70/153, Q2, IF- 1.257, CI - 17) 22. Magen E, Mishal J, Feldman VK, Kidon M, Schlesinger M, Sthoeger Z. Increased platelet volume and CRP in spontaneous chronic urticaria patients with a positive autologous serum skin test. Am J Med Sci. 2010; 339(6):504-508. (jR: 70/153, Q2, IF- 1.257, CI - 53) 23. Magen E, Mishal J, Schlesinger M. Impact of contact sensitization in chronic spontaneous urticaria. Am J Med Sci. 2011; 341(3):202-206. (jR: 65/155, Q2, IF- 1.391, CI - 8) 24. Magen E, Mishal J, Schlesinger M. Clinical and laboratoty features of antihistamine resistant chronic spontaneous urticaria. Allergy Asthma Proc. 2011 Nov-Dec; 32(6):460-466. (jR: 13/24, Q3, IF- 2.170, CI – 32) 25. Magen E, Mishal J. The effect of L-thyroxine treatment on chronic idiopathic urticaria and autoimmune thyroiditis. Int J Dermatol. 2012 Jan; 51(1):94-97. (jR: 34/59, Q3, IF- 1.342, CI - 22) 26. Magen E, Mishal J, Zeldin Y, Schlesinger M. Antihistamines do not inhibit the wheal induced by the intradermal injection of autologous serum in resistant chronic idiopathic urticaria. Allergy Asthma Proc. 2012 Nov-Dec; 33(6):531-537. (jR: 13/23, Q3, IF- 2.193, CI - 6) 27. Magen E, Mishal J. Possible benefit from treatment of Helicobacter pylori in antihistamine-resistant chronic urticaria. Clin Exp Dermatol. 2013; 38(1):7-12. (jR: 41/61, Q3, IF – 1.234, CI - 26) 28. Magen E, Schlesinger M, Hadari I. Chronic urticaria can be triggered by eradication of Helicobacter pylori. Helicobacter. 2013; 18(1):83-87 (jR: 27/75, Q2, IF – 2.993, CI - 16) 29. Magen E, Mishal J, Schlesinger M. Clinical and laboratory features of chronic idiopathic urticaria in the elderly. Int J Dermatol. 2013; 52(11):1387-1391. (jR: 42/61, Q3, F- 1.227, CI - 22) 30. Magen E, Bychkov V, Ginovker A, Kashuba E. Chronic Opisthorchis felineus Infection Attenuates Atherosclerosis - An Autopsy Study. Int J Parasitol. 2013; 43(10):819-824. (jR: 7/37, Q1, IF- 3.404, CI - 22) 31. Magen E, Mishal J, Schlesinger M. Chronic idiopathic angioedema: a single center experience. Int J Dermatol. 2014; 53(10): e421-e427. (jR: 38/63, Q3, IF- 1.312, CI - 3) 32. Kuznik BI, Vitkovsky YA, Gvozdeva OV, Solpov AV, Magen E. Lymphocyte – platelet crosstalk in Graves' disease. Am J Med Sci. 2014; 347(3):206-210. (jR: 71/154, Q2, IF- 1.389; CI - 9) 33. Magen E, Schlesinger M, David M, Ben-Zion I, Vardy D. Selective IgE deficiency, immune dysregulation and autoimmunity. Allergy Asthma Proc. 2014; 35(2): e27-e33 (jR: 8/24, Q2, IF- 3.061, CI - 28) 34. Magen E, Schlesinger M, Ben-Zion I, Vardy D. Helicobacter pyloriinfection in patients with selective IgE deficiency. World J Gastroenterol. 2015; 21(1):240-245. (jR: 38/79, Q2; IF 2.787, CI -4). 35. Magen E, Waitman D, Dickstein Y, Davidovich V, Kahan N. Clinical-laboratory characteristics of ANA positive chronic idiopathic urticaria. Allergy Asthma Proc. 2015; 36(2):138-144 (jR: 11/25, Q2, IF- 2.709, CI -18) 36. Magen E, Mishal J, Vardy D. Selective IgE deficiency and cardiovascular diseases. Allergy Asthma Proc. 2015; 36(3):225-259. (jR: 11/25, Q2, IF-2.709, CI - 10) 37. Tsybikov NN, Petrisheva IV, Kuznik BI, Magen E. Plasma endothelin-1 levels during exacerbation of atopic dermatitis. Allergy Asthma Proc. 2015; 36(4):320-324. (jR: 11/25, Q2, IF- 2.709; CI -18) 38. Tsybikov NN, Egorova EV, Fefelova EV, Kuznik BI, Magen E. Expression of TLR2 and TLR4 on peripheral blood monocytes during exacerbation of atopic dermatitis. Allergy Asthma Proc. 2015; 36(6):e140-e145. (jR: 11/25, Q2, IF-2.709; CI - 9) 39. Tsybikov NN, Egorova EV, Fefelova EV, Kuznik BI, Magen E. Anti-cytokine autoantibodies in chronic rhinosinusitis. Allergy Asthma Proc. 2015; 36(6):473-480. (jR: 11/25, Q2, IF- 2.709 CI - 10) 40. Tsybikov NN, Egorova EV, Fefelova EV, Kuznik BI, Magen E. Neuron-specific Enolase in nasal secretions as a novel biomarker of olfactory dysfunction in chronic rhinosinusitis. Am J Rhinol Allergy. 2016 Jan; 30(1):65-69. (jR: 14/42; Q2, IF-1.955, CI -8) 41. Tsybikov NN, Egorova EV, Kuznik BI, Fefelova EV, Magen E. Biomarker assessment in chronic rhinitis and chronic rhinosinusitis: Endothelin-1, TARC/CCL17, neopterin, and α-defensins. Allergy Asthma Proc. 2016 Jan-Feb; 37(1):35-42. Allergy Asthma Proc. 2016 Jan; 37(1):35-42. (jR: 18/26, Q3, IF- 2.614; CI - 19) 42. Tsybikov NN, Petrisheva IV, Fefelova EV, Kuznik BI, Magen E. Plasma α-defensins are elevated during exacerbation of atopic dermatitis. Clin Exp Dermatol. 2016 apr; 41(3):253-259. (jR: 36/63, Q3, IF – 1.589; CI - 5) 43. Tsybikov NN, Egorova EV, Fefelova EV, Kuznik BI, Magen E. HSP70 and anti HSP70 antibodies in nasal secretions of patients with chronic rhinosinusitis. Allergy Rhinol (Providence). 2016; 7(1):E14-E20. (JR: N/A, IF- N/A; Q – N/A; CI - 1). 44. Magen E, Waitman DA, Goldstein N, Schlesinger M, Dickstein Y, Kahan N. Helicobacter pylori infection in patients with selective immunoglobulin A deficiency. Clin Exp Immunol. 2016 Jun; 184(3):332-337. (JR: 61/151 Q2, IF-3.410; CI - 7). 45. Magen E, Zueva E, Mishal J, Schlesinger M. The clinical and laboratory characteristics of acute spontaneous urticaria and its progression to chronic spontaneous urticaria. Allergy Asthma Proc. 2016 Sep;37(5):394-399 (jR: 18/26, Q3, IF- 2.614; CI- 16) 46. * Magen E, Masalha A, Waitman DA, Kahan N, Viner I, Klassov L, Vardy D. Prevalence of dermatologic diseases among patients with selective immunoglobulin A deficiency. Allergy Asthma Proc. 2017 Jan 1; 38(1):70-77. (jR: 18/27, Q3, IF- 2.213; CI - 8) 47. * Shalom G*, Magen E*, Dreiher J, Freud T, Bogen B, Comaneshter D, Vardy DA, Khoury R, Agmon-Levin N, Cohen AD. (* equal controbutions). Chronic Urticaria and the Metabolic Syndrome: a cross-sectional community-based study of 11 261 patients. J Eur Acad Dermatol Venereol. 2018 Feb; 32(2):276-281 (jR: 6/66, Q1, IF- 5.113; CI - 24) 48. * Magen E, Waitman DA, Kahan N. Association of Alopecia Areata with Atopic Dermatitis and Chronic Spontaneous Urticaria. Allergy Asthma Proc. 2018 Mar 1; 39(2):96-102. (jR: 19/27, Q3, IF- 2.124; CI - 14) 49. * Shalom G, Kridin K, Babaev M, Magen E, Tiosano S, Dreiher J, Horev A, Khury R, Comaneshter D, Agmon-Levin N, Cohen AD. Chronic urticaria and osteoporosis: a longitudinal, community-based cohort study of 11 944 patients. Br J Dermatol. 2019 May; 180(5):1077-1082. (jR: 4/68, Q1, IF- 7.000; CI – 7) 50. * Magen E, Chikovani T, Waitman DA, Kahan NR. Factors related to omalizumab resistance in chronic spontaneous urticaria. Allergy Asthma Proc. 2019 Jul 1; 40(4):273-278. (jR: 19/28, Q3, IF- 2.414, CI 10) 51. * Magen E, Waitman DA, Kahan N. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria. Allergy Asthma Proc. 2021 Jan 1;42(1): e17-e24 (jR: 21/27, Q4, IF- 2.873; CI - 3) 52. * Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E. COVID-19 Susceptibility in bronchial Asthma. J Allergy Clin Immunol Pract. 2021 Feb; 9(2):684-692.e1 (JR: 3/27, Q1, IF -11.022; CI - 26). 53. * Khavinson VK, Kuznik BI, Trofimova SV, Volchkov VA, Rukavishnikova SA, Titova ON, Akhmedov TA, Trofimov AV, Potemkin VV, Magen E. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021 Feb; 17(1):285-290. (JR: 34/139, Q1, IF 6.692; CI - 1) 54. * Magen E, Blum I, Waitman DA, Kahan N, Forer B. Autoimmune Inner Ear Disease among Patients with Selective IgA Deficiency. Audiol Neurootol. 2021; 26(2):127-134. (jR: 15/27, Q3, IF – 2.213, CI 0) 55. * Lauden A, Geishin A, Merzon E, Korobeinikov A, Green I, Golan-Cohen A, Vinker S, Manor I, Weizman A, Magen E. Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. Brain Behav Immun Health 2021 Jul 30; 16:100313. (jR: N/A, Q – N/A, IF – N/A, CI - 1) 56. * Merzon E, Green I, Vinker S, Golan-Cohen A, Gorohovski A, Avramovich E, Frenkel-Morgenstern M, Magen E. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection. FEBS J. 2021 Sep; 288(17):5179-5189. (jR: 88/296, Q2, IF – 5.622, CI 16) 57. * Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, Ruppin E, Magen E, Vinker S. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection : test negative design study. British Medical Journal; NOV 25 2021, 1-7;(jR: 4/172, Q1, IF – 93.333, CI 26) 58. * Israel A, Shenhar Y, Green I, Merzon E, Golan-Cohen A, Schäffer AA, Ruppin E, Vinker S, Magen E. Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection; Vaccines (Basel); 2021 Dec 31; 10(1):64. (JR:77/161, Q2, IF 4.961, CI 56) 59. * Magen E, Yakov A, Green I, Israel A, Vinker S, Merzon E. Chronic spontaneous urticaria after BNT162b2 mRNA vaccination against SARS-CoV-2. Allergy Asthma Proc. 2022 Jan 1; 43(1):30-36 (JR: 21/27, Q4, IF- 2.873, CI - 2). 60. * Israel A, Merzon E, Shenhar Y, Green I, Golan-Cohen A, Schäffer AA, Ruppin E, Vinker S, Magen E. Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination. Vaccines (Basel). 2022 Apr 19;10(5):636. (JR:77/161, Q2, IF 4.961, CI 0) 61. * Israel A, Schäffer AA, Merzon E, Green I, Magen E, Golan-Cohen A, Vinker S, Ruppin E. A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received. Microorganisms. 2022 Jun 16;10(6):1238. (JR:54/136, Q2, IF 4.929, CI 0) 62. * Green I, Merzon E, Golan-Cohen A, Vinker S, Israel A, Magen E. A higher frequency of physical activity is associated with reduced rates of SARS-CoV-2 infection. European Journal of General Practice. 2022 Nov 7;1-7). (JR:4/18, Q1, IF 3.636, CI 0) 63. * Magen E, Merzon E, Green I, Golan-Cohen A, Vinker S, Israel A. Selective IgA deficiency and COVID-19. J Allergy Clin Immunol Pract. 2023 Feb 28:S2213-2198(23)00220-9 ((JR: 3/27, Q1, IF -11.022) 64. * Magen E, Merzon E, Green I, Magen I, Waitman DA, Kahan NR. A comparative study of chronic spontaneous urticaria and chronic mast cell mediated angioedema. Allergy Asthma Proc. 2023 Mar 1;44(2):122-129. (JR: 13/38, Q2, IF 2.873) 65. * Magen E, Merzon E, Green I, Magen I, Geishin A, Golan-Cohen A, Vinker S, Israel A. Chronic idiopathic eosinopenia and chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2023 Apr 21:S2213-2198(23)00413-0. (JR: 3/27, Q1, IF -11.022) 66. *Israel A, Berkovitch M, Merzon E, Golan-Cohen A, Green I, Ruppin E, Vinker S, Magen E. Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019. Clin Infect Dis. 2023 Oct 5;77(7):972-975. (JR: 10/96, Q1, IF 11.8) 67. *Magen E, Geishin A, Merzon E, Green I, Golan-Cohen A, Vinker S, Israel A. Prevalence of neurological diseases among patients with selective IgA deficiency. Allergy Asthma Proc. 2023 Sep 1;44(5):e17-e21. (JR: 13/38, Q2, IF 2.873) 68. * Israel A, Schäffer AA, Berkovitch M, Ozeri DJ, Merzon E, Green I, Golan-Cohen A, Ruppin E, Vinker S, Magen E. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Long-Term Risk of Immune-Related diseases. Front Immunol. 2023 Sep 11;14:1232560. (JR; 35/161, Q1, IF-8.787) 69. Kulumbegov B, Chikovani T, Gotua M, Kikodze N, Magen E. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria. Allergy Asthma Proc. 2023 Nov 1;44(6):429-435. (JR: 13/38, Q2, IF 2.873) 70. *Magen E, Merzon E, Green I, Golan-Cohen A, Vinker S, Israel A. A case-control study for comorbidity and laboratory factors associated with food-induced anaphylaxis. Allergy Asthma Proc. 2024 Jan 1;45(1):53-60. (JR: 13/38, Q2, IF 2.873) 71. *Magen E, Merzon E, Green I, Golan-Cohen A, Vinker S, Israel A. Dermatological Comorbidities in Patients with Acute Urticaria. Acta Derm Venereol. 2024 Mar 22;104:adv18399. doi: 10.2340/actadv.v104.18399. (JR: 7/68, Q1, IF – 4.016) 72. * Merzon E#, Magen E#, Ashkenazi S, Weizman A, Manor I, Krone B, Green I, Golan-Cohen A, Vinker S, Faraone S, Israel A. (#equal contribution). The association between glucose 6-phosphate dehydrogenase (G6PD) deficiency and attention deficit/hyperactivity disorder (ADHD). Nutrients 2023 (accepted). (JR: 17/88, Q1, IF – 5.9) 73. * Rubeiz CJ, Asero R, Betschel S, Craig T, Grumach A, Hide M, Lang D, Levin M, Longhurst H, Magen E, Maurer M, Saini R, Sussman G, Toubi E, Van DN, Zuberier T, Bernstein JA. Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria. World Allergy Organ J. 2024 Jan 3;17(1):100858. 74. Israel A, Merzon E, Krone B, Faraone SV, Green I, Golan Cohen A, Vinker S, Cohen S, Ashkenazi S, Magen E, Weizman A, Manor I. The Association Between Repeated Measured Febrile Episodes During Early Childhood and Attention Deficit Hyperactivity Disorder: A Large-Scale Population-Based Study. J Atten Disord. 2024 Mar;28(5):677-685. 75. Magen E, Vinker-Shuster M, Merzon E, Green I, Magen I, Golan-Cohen A, Israel A. Chronic idiopathic eosinopenia, allergic, and autoimmune disorders. J Allergy Clin Immunol Pract. 2024 Jul;12(7):1933-1936.e1. 76. Israel A, Raz I, Vinker S, Magen E, Green I, Golan-Cohen A, Berkovitch M, Merzon E. Type 2 Diabetes in Patients with G6PD Deficiency. N Engl J Med. 2024 Aug 8;391(6):568-569. 77. Magen E, Merzon E, Green I, Magen I, Golan-Cohen A, Vinker S, Israel A. Acute urticaria and cardiovascular diseases. Am J Med Sci. 2024 Aug 8:S0002-9629(24)01397-1. 78. Magen E, Ozeri D, Merzon E, Vinker S, Israel A. Dermatological Comorbidities in Patients with Familiar Mediterranean Fever. Acta Derm Venereol. 2024 Aug 15;104:adv39988. 79. Magen E, Merzon E, Vinker Shuster M, Green I, Magen I, Golan-Cohen A, Israel A. Prevalence of Helminth Infections in Patients with Celiac Disease. Dig Dis. 2024 Aug 22:1-7. doi: 10.1159/000539581. 80. Magen E, Geishin A, Weizman A, Merzon E, Green I, Magen I, Yakov A, Manor I, Ashkenazi S, Vinker S, Israel A. High rates of mood disorders in patients with chronic idiopathic eosinopenia. Brain Behav Immun Health. 2024 Aug 12;40:100847. 81. Merzon E, Farag R, Ashkenazi S, Magen E, Manor I, Weizman A, Green I, Golan-Cohen A, Genshin A, Vinker S, Israel A. Increased Prevalence of Attention Deficit Hyperactivity Disorder in Individuals with Selective Immunoglobulin A Deficiency: A Nationwide Case-Control Study. J Clin Med. 2024 Oct 12;13(20):6075. Case reports 82. Mishal J, Sherer Y, Magen E, Lugasi G. Transient polycythemia and multi-organ failure due to acute alcohol ingestion. Ann Hematol. 2000;79(10):596-597 (jR: 31/60, Q3, IF – 1.448, CI - 0) 83. Magen E, Feldman V. Autoimmune progesterone anaphylaxis in 24-year-old woman. Isr Med Assoc J. 2012; 14(8):518-519. (jR: 83/155, Q3, IF – 0.978, CI - 7) 84. Magen E, Feldman V, Joseph M, Israel H. Symptomatic Secondary Selective IgM Immunodeficiency in Adult Man with Undiagnosed Celiac Disease. Case Reports Immunol. 2012; 2012:684247. (JR: N/A, IF-N/A, Q – N/A, CI - 0) 85. Magen E. Beneficial effect of sauna therapy on severe antihistamine resistant chronic urticaria. Isr Med Assoc J. 2014 Mar; 16(3):182-183. (JR: 91/154, Q3, IF – 1.013, CI - 0) 86. Magen E, Chikovani T. Case report of irritable bowel syndrome responding to Omalizumab. Georgian Med News. 2015; (243):42-45 (Jr: NA; Q - NA, IF – NA, CI – 6). 87. * Magen E, Masalha A, Zueva E, Vardy D. Possible autoimmune primary ovarian insufficiency in patients with selective IgA deficiency. Isr Med Assoc J. 2018 Mar; 20(3):192-193. (JR: 125/160, Q4, IF – 0.828; CI - 1) 88. * Magen E. Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria. Acta Derm Venereol. 2019 Sep 1; 99(10):919-920. (JR: 7/68, Q1, IF – 4.016; CI - 3) 89. * Magen E, Bar-Yishay M, Korobeinikov A. Food allergy-exacerbated atypical hidradenitis suppurativa. J Allergy Clin Immunol Pract. 2020 Sep; 8(8):2826-2827. (JR: 3/28, Q1, IF 8.861; CI-1) 90. * Magen E, Chikovani T. Recurrent spontaneous clearance of psoriasis during exacerbations of concomitant chronic spontaneous urticaria. Clin Case Rep. 2020 May 25; 8(8):1544-1546. (JR: N/A, IF- N/A, Q – N/A, CI – 0). 91. * Mishal J, Viner I, Livoff A, Maayan S, Magen E. Sweet Syndrome and Secondary Syphilis in a Person with Acute Necrotizing Tonsillitis. Case Rep Dermatol 2021; 13:216–221 (JR: N/A, IF-N/A, Q - N/A, CI - 1) 92. Rozov A, Dubov V, Cherniavsky E, Magen E. Vertebral Body Avascular Osteonecrosis: An Unusual Late Complication of Tracheostomy. Cureus. 2022 Feb 25; 14(2):e22603. (JR: N/A, N/A, IF N/A; CI-0) 93. * Magen E, Komarova I, Magen I, Phirtskhalava S. Case of benralizumab-induced exacerbations of chronic spontaneous urticaria. Clin Case Rep. 2022 Jun 19; 10(6):e05930. (JR: N/A, N/A, IF N/A; CI-0) 94. * Magen E, Mukherjee, S, Bhattacharya M, Detroja R, Merzon E, Blum I, Livoff A, Shlapobersky M, Baum G, Talisman R, Cherniavsky E, Dori A, Frenkel-Morgenstern M. Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis. Vaccines (Basel). 2022, 10(7), 1135 (JR: 77/161, Q2, IF 4.961, CI 0) Invited reviews in peer reviewed scientific journals 95. Magen E, Viskoper RJ. Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases. Isr Med Assoc J. 2000; 2(12):929-934 (JR: 105/105, Q4, IF – 0.027, CI - 5) 96. Magen E, Elbirt D, Sthoeger Z. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus. Isr Med Assoc J. 2005; 7(4):252-256. (JR: 76/105, Q3, IF – 0.547, CI - 4) 97. Magen E, Borkow G, Bentwich Z, Mishal J, Scharf S. Can worms defend our hearts? Chronic helminthic infections may attenuate the development of cardiovascular diseases. Med Hypotheses. 2005; 64(5):904-909. (jR: 57/72 Q4, IF- 0.920, CI - 35) 98. Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol. 2014 Feb 14; 20(6):1510-1516 (JR: 41/76, Q3; IF 2.369, CI - 35). 99. Magen E, Chikovani T. Possible therapeutic role of IgE blockade in irritable bowel syndrome. World J Gastroenterol. 2016 Nov 21; 22(43):9451-9456. (JR: 30/79, Q2; IF 3.365; CI - 6). (Editorial) 100. Janikashvili N, Samson M, Magen E, Chikovani T. Immunotherapeutic Targeting in Autoimmune Diseases. Mediators Inflamm. 2016; 2016:1432702. (JR: 69/151, Q2; IF - 3.232; CI - 1). (Editorial) Research Letters 101. * Shalom G*, Magen E*, Dreiher J, Freud T, Bogen B, Comaneshter D, Vardy DA, Khoury R, Agmon-Levin N, Cohen AD.. Chronic Urticaria and Atopic Disorders: a Cross-sectional Study of 11,271 Patients. Br J Dermatol. 2017 Oct; 177(4): e96-e97. (jR: 4/64, Q1, IF- 6.129; CI-11) (* equal controbutions) 102. * Shalom G*, Magen E*, Babaev M, Horev A, Freud T, Ben Yakov G, Comaneshter D, Vardy DA, Cohen AD. Chronic Urticaria and Irritable Bowel Syndrome: a Cross-Sectional Study of 11,271 Patients. Br J Dermatol. 2018 Mar; 178(3): e204-e206. (jR: 3/66, Q1, IF- 6.714; CI - 10) (* equal contribution). Letter to the editors 103. Magen E, Boris IK. Letters to the Editor- Untitled. Allergy Asthma Proc. 2016 Jul; 37(4):48-9. (JR: 18/26, Q3, IF- 2.614; CI 0) 104. * Magen E, Chikovani T. Development of angio-oedema after Omalizumab injections in a patient with chronic spontaneous urticaria. Clin Exp Dermatol. 2018 Oct; 43(7):825. (JR: 38/66, Q3, IF – 1.771; CI - 0) 105. * Magen E, Chikovani T. A case of food-dependent exercise-induced Angioedema. Allergy Clin Immunol Pract. 2019 Jan; 7(1):312-313. (JR: 3/28, Q1, IF- 7.574; CI – 2) Clinical Communications 106. * Magen E, Geishin A, Lauden A. Rapid improvement of Treatment-resistant Major depression during the administration of Low-dose oxycodone. J Clin Psychopharmacol. 2021 Jan/Feb 01; 41(1):81-83. (JR: 101/155, Q3, IF- 3.118, CI - 0) 107. * Magen E, Landman S. New Onset of Vitiligo and Atopic Dermatitis-Like Eczematous Dermatitis after Pfizer BioNTech's BNT162b2 Vaccination. Dermatitis. 2022 Apr 28. Online ahead of print. (JR: 14/68, IF- 4.867, Q1, CI - 0) 108. Green I, Merzon E, Vinker S, Golan-Cohen A, Israel A, Scheinowitz M, Ishai R, Magen E, Ashkenazi S. Author's reply to comment on: A higher frequency of physical activity is associated with reduced rates of SARS-CoV-2 infection. Eur J Gen Pract. 2023 Dec;29(2):2188015. (JR:4/18, Q1, IF 3.636) Study Group 103. Pett SL, Wand H, Law MG, Arduino R, Lopez JC, Knysz B, Pereira LC, Pollack S, Reiss P, Tambussi G; ESPRIT Research Group. Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants. HIV Clin Trials. 2006; 7(2):70-85. (jR: 114/199 Q3, IF- 1.704, CI - 5) 104. ESPRIT Research Group, Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2. HIV Med. 2007;8(2):112-23. (jR: 12/50 Q1, IF- 3.347, CI - 8) 105. ESPRIT Study Group. Members of the writing group for the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)–Evaluation of Subcutaneous Proleukin in a Randomized International Trial and the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15; 361(16):1548-1559. (jR: 1/100 Q1, IF- 47.050, CI - 283) 106. INSIGHT-ESPRIT Study Group. Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). HIV Med. 2011 Apr; 12(4):219-27. (JR: 28/70 Q2, IF- 3.006, CI - 4) 107. INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc. 2014; 3(3): e000844. (jR: 24/123 Q1, IF- 4.306, CI - 136) 108. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D: A: D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D: A: D study. PLoS Med. 2015; 12(3): e1001809. (JR: 7/155 Q1, IF 13.585, CI - 97) 109. * Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G, Shi V, Zhao Z, Cowie MR; PARALLAX Investigators and Committee members. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients with Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. JAMA. 2021 Nov 16; 326(19):1919-1929. (JR: 3/167 Q1, IF 56.274, CI - 9) Professional articles and publications 110. Magen E, Bentwich Z. Treatment for HIV infection during pregnancy and delivery. Israeli Journal of Obstetrics and Gynecology 2003; 1:16-21(jR: NA, Q - NA, IF – NA, CI - 0) 111. Elbirt D, Magen E, Sthoeger Z. Metabolic disturbances and cardiovascular diseases in HIV. www.multimedia.co.il, living with AIDS. 2010; 19-22 (jR: NA, Q - NA, IF – NA, CI - 0) 112. Gabbay J, Mishal J, Magen E, Zatcoff R, Shemer-Avni Y, Borkow G. Copper Oxide Impregnated Textiles with Potent Biocidal Activities. Journal of Industrial Textiles. 2005, 4; 78-83 (jR: NA, Q - NA, IF - NA, CI - 234). 113. Schlesinger M, Magen E, Sthoeger Z. The complement system, mechanisms of action, deficiency states and treatment options. www.multimedia.co.il Israeli journal of medicine. 2012; (29);24-8 (jR: NA, Q - NA, IF – NA, CI - 0) 114. Elbirt D, Asher I, Broda K, Werner B, Mahlev-Guri K, Gradstein S, Burke M, Cohen Y, Tadessa S, Radain-Sade S, Magen E, Sthoeger Z. Israeli-Migrants from Sub-Saharan Africa (Ethiopia) and HIV: Medical and Social Issues - The Experience of One Major HIV Center. Int Public Health J 2010; 2(3):329-347 (jR: NA, Q - NA, IF – NA) 115. * Kuznik BI, Davydov SO, Guseva ES, Stepanov AV, Smolyakov YN, Tsybikov N, Fine I, Magen E. Relationship between selected populations of leukocytes and cardiovascular system activity in women with essential hypertension. Systemic Hypertension (Russian Journal). 2017; 14 (4): 32-37 (IF N/A, JR N/A, Q N/A). 116. * Guseva Е.S, Davydov S.О, Kuznik B.I, Smolyakov Y.N, Stepanov А.V, Fine I.V, Magen E. The role of growth differentiation factor 11 (GDF11) in regulation of lipid metabolism and cardiohemodynamic functions in essential hypertension patients in moderate effort exercises. Russ J Cardiol 2018, 4 (156): 93–98 (JR; NA; NA, IF – NA). 117 * Magen E, Shalom G, Waitman DA, Kahan N. Chronic spontaneous urticaria following vaccination. International Journal of Advanced Research. 2018, 6 (Feb) 1434-1439 (jR: NA, Q - NA, IF – NA, CI - 0) 118 * Kuznik BI, Davydov SO, Stepanov AV, Guseva ES, Smolyakov YN, Tsybikov NN, Magen E. The Role of Growth Differentiation Factors 11 and 15 (GDF11, GDF15), Eotaxin-1 (CCL11) and Junctional Adhesion Molecule a (JAM-A) in the Regulation of Blood Pressure in Women with Essential Hypertension. MOJ Gerontol Ger. 2018;3(1):71-75 ((jR: NA, Q - NA, IF – NA, CI - 2) 119 * Kuznik B., Khavinson V., Lukyanov S. Tereshkov P, Konnov V, Magen E. Effect of tocilizumab and thymalin on systemic inflammation in patients with COVID-19. Vrach; ВРАЧ (Russian) 2020; 31 (11): 87–96. (jR: NA, Q - NA, IF – NA) 120 * Lukianov S, Kuznik B, Khavinson V, Shapovalov K, Smolyakov Y, Tereshkov P, Konnov V, Magen E. The use of Thymalin to correct the immune status deviations in COVID-19 (Rationale for the use of drug and a clinical case). Vrach ВРАЧ (Russian); 2020; 31 (8):74-82 (jR: NA, Q - NA, IF – NA) 121* Lukyanov SA, Kuznik BI, Shapovalov KG, Khavinson VK, Smolyakov YN, Tereshkov P, Konnov V, Magen E. Thymalin as a Potential Alternative in the Treatment of Severe Acute Respiratory Infection Associated with SARSCoV-2. Int J Immunol Immunother 2020; 7:055 (jR: NA, Q - NA, IF – NA) 122 * Smolyakov YN, Tereshkov PK, Shapovalov YK, Konnov VA, Magen E. Immunomodulation with Thymalin in the COVID-19 Related Cytokine Storm: Case Reports. 2020 - 10(6). American Journal of Biomedical Science & Research. MS.ID.001574. DOI: 10.34297/AJBSR.2020.10.001574 (jR: NA, Q - NA, IF – NA) 123 * Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, Ruppin E, Magen E, Vinker S. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. MedRxiv [Preprint]. 2021 Aug 5:2021.08.03.21261496. (jR: N/A, Q – N/A, IF – N/A, CI 17) 124 * Israel A, Shenhar Y, Green I, Merzon E, Golan-Cohen A, Schäffer AA, Ruppin E, Vinker S, Magen E. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. MedRxiv [Preprint]. 2021 Aug 21:2021.08.19.21262111. (jR: N/A, Q – N/A, IF – N/A, CI 5) Abstracts 125 Viskoper JR, Magen E, Feldman A, Priluk R, Last A, London A, Michaeli D, Altshuler A. Influence of low dose aspirin and simvastatin on blood pressure, flow-dependent vasodilatation, tonus and elasticity of brachial artery in hypertensive nonhyperlipidemic subjects. Am J Hypertens 2000, 13 (S2): 11A (abstract meeting) (jR: 16/45 Q2, IF-2.685, CI – 0) 126 Magen E, Berezovsky A, Priluk R, Last-Pollak M, Laszt A, London D, Viskoper R. Atorvastatin, but not vitamin C can improve blood pressure control in patients with resistant arterial hypertension and hyperlipidemia. Journal of Hypertension. 2002, 20, S241-S241 ((jR: 8/45 Q1, IF- 3.640 CI-5) 127 Magen E. Contact allergies in patients with chronic urticaria. Annals of Allergy, Asthma & Immunology 2011, 107 (5), A17-A17 (jR: Allergy 7/24 Q2, IF- 2.833 CI - 0) 128 . * Asher I, Magen, E, Vaddas, Z, Tubi E, Mahlab GK, Sthoeger Z. Long term (> 1 year) treatment of chronic spontaneous urticaria with Omalizumab-A real life study. ALLERGY 2020; (75) SI ‏ 109 (abstract meeting) 196-196 (JR: 1/28 Q1, IF- 13.146 CI - 0) 14. Lecture and Presentations at National and International Meetings Invited Lectures: 1. Magen E. Office blood pressure measurement versus home blood pressure monitoring in assessment of blood pressure control of hypertensive subjects. WHO Collaborative Center for Prevention of Cardiovascular Diseases. 15-th European Congress of Cardiovascular Research. Amsterdam. Holland, 1999 2. Magen E. Effects of low dose aspirin and simvastatin on blood pressure and endothelial dysfunction of hypertensive subjects with and without hyperlipidemia. Scientific Meeting of the American Society of Hypertension, 16 - 20 May 2000, New. York, USA. 3. Magen E, Effectiveness of Measurement of arterial elasticity and tonus by pulse echo device inta-medics ltd. Israeli Society of Hypertension congress, Tel Aviv. November 15, 2000 4. Magen E. Use of statins versus AT 1 blocker as first line monotherapy in patients with borderline essential arterial hypertension without hyperlipidemia. Rambam Medical Center, Haifa. Israeli Society of Hypertension congress, December 7, 2001 5. Magen E. Atorvastatin, but not vitamin C can improve blood pressure control in patients with resistant arterial hypertension and hyperlipidemia. 7th International Symposium on Hypertension in the Community, Tel Aviv. Israel 2001 6. Magen E. Effects of low dose aspirin and simvastatin on blood pressure and endothelial dysfunction of hypertensive subjects with and without hyperlipidemia. International Symposium on Hypertension in the Community. Tel Aviv. Israel 2002 7. Magen E. Eradication of helicobacter pylori infection can facilitate immune reconstitution in patients with HIV-1 infection. XV International AIDS Conference. Bangkok, Thailand 2004 8. Magen E. Phase I/II clinical trial of the peptide nucleic acid complex "Product R" in patients with advanced-stage acquired immunodeficiency syndrome. World AIDS Congress, Glasgow, UK, October 21, 2004 9. Magen E. Resistant arterial hypertension and hyperlipidemia, Atorvastatin is better than vitamin C for blood pressure control. The 75th European Atherosclerosis Society congress, Prague, Czech Republic, April 2005 10. Magen E. Resistant arterial hypertension and hyperlipidemia, Statins and bloood pressure control. Israeli Society of Hypertension, Annual Meeting. Tel Aviv. Israel 2005 11. Magen E. Chronic helminthic Infections may attenuate the development of cardiovascular diseases. XXV Congress of the European Academy of Allergology and Clinical Immunology, 10-14 June 2006, Vienna, Austria. 12. Magen E. Hygiene hypothesis and development of cardiovascular diseases. XIV International Symposium on Atherosclerosis. June 18 - 22, 2006; Rome, Italy 13. Magen E. Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. Israeli Society of Hypertension, Annual Meeting. Tel Aviv. Israel 2006 14. Magen E. Treatment of allergic rhinitis can improve blood pressure control. The XVII European Meeting on Hypertension. Milan June 15-19; 2007, Italy. 15. Magen E. Treatment of allergic rhinitis can improve blood pressure control. Israeli Society of Hypertension, Annual Meeting. Tel Aviv. Israel 2007 16. Magen E. Treatment of allergic rhinitis can improve blood pressure control. Israeli Society of Allergy and Clinical Immunology Annual Congress, Jerusalem. Israel 2007 17. Magen E. Sensitizations to allergens of TRUE test in 864 consecutive eczema patients in Israel. Israeli Society of Allergy and Clinical Immunology Annual Congress, Annual Meeting. Tel Aviv. Israel 2007 18. Magen E. Immunomodulation by small peptides; Advances in Gerontology. Institute of Bioregulation and Gerontology, St. Petersburg, Russia, June 10, 2007 19. Magen E. Eradication of Helicobacter pylori infection improves chronic urticaria. 18th European Congress of Clinical Microbiology and Infectious Diseases. April 19-22, 2008 Barcelona, Spain 20. Magen E. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. Israeli Society of Allergy and Clinical Immunology Annual Congress, Tel Aviv. Israel 2008 21. Magen E. Eradication of Helicobacter pylori infection equally improves chronic urticaria with positive and negative autologous serum skin test. XXVII Congress of the European Academy of Allergology and Clinical Immunology, Barcelona, Spain, June 11, 2008. 22. Magen E. Efficacy of nasal Staphylococcus aerius eradication by topical nasal mupirocin in patients with perennial allergic rhinitis. World Congress of Asthma/INTERASMA, 5 -8 November, 2008, Monaco. 23. Magen E. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. Israeli Society of Allergy and Clinical Immunology Annual Congress, Tel Aviv. Israel 2009 24. Magen E. Arterial hypertension and complement C3. Israeli Society of Hypertension, Annual Meeting. Tel Aviv. Israel 2009 25. Magen E. Eradication of helicobacter pylori infection can facilitate immune reconstitution in patients with HIV-1 infection. Israeli Society of Allergy and Clinical Immunology Annual Congress, Tel Aviv. Israel 2009 26. Magen E. Eradication of helicobacter pylori infection can facilitate immune reconstitution in patients with HIV-1 infection. The 3rd HIV/AIDS Conference in Eastern Europe and Central Asia, EECAAC, 28-30 October, 2009 Moscow, Russian Federation. 27. Magen E. Immunological aspects of arterial hypertension. Allergology and Clinical Immunology Annual Meeting, 1-3 October 2010, Tbilisi, Georgia. 28. Magen E. Autoimmune progesterone skin diseases and anaphylaxis. Israeli Society of Allergy and Clinical Immunology Annual Congress, Tel Aviv. Israel 2010 29. Magen E. Eradication of Helicobacter pylori infection improves chronic urticaria with positive and negative autologous serum skin test. EPS Global 1st International Immunology Conference, Shanghai, China, September 11, 2010. 30. Magen E. Allergic diseases in primary care. Israeli Society of Family Medicine Annual Congress, Tel Aviv, September 27, 2010 31. Magen E. Impact of contact sensitization in chronic spontaneous urticaria. The 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) November 3-8, 2011, in Boston, Massachusetts, USA. 32. Magen E. Allergic emergencies its management in primary care. Israeli Society of Family Medicine Annual Congress, Tel Aviv. Israel 2011 33. Magen E. L-Thyroxine treatment is not effective in patients with Chronic Idiopathic Urticaria and Thyroid Autoimmunity. Israeli Society of Allergy and Clinical Immunology Annual Congress, Tel Aviv. Israel 2011 34. Magen E. Principles specific allergen immunotherapy and immunomodulation. Tel Aviv University, Israeli Society of Family Medicine Annual Meeting, Tel Aviv. Israel November 14, 2011 35. Magen E. Antihistamines do not inhibit the wheal induced by the intradermal injection of autologous serum in resistant chronic idiopathic urticaria. The 8th International Congress on Autoimmunity; Granada, Spain, 9-13 May, 2012. 36. Magen E. Biologicals in atopy and in systemic inflammatory diseases and beyond. Thev Interest Group on Biological Immune Response Modifiers at the EAACI Executive Committee, Geneva, Switzerland, June 17, 2012 37. Magen E. Antihistamine resistant chronic idiopathic urticaria. VII Congress of Allergy, Asthma and Immunopathology; Batumi, Georgia, October 8, 2012 38. Magen E. Invited foreign professors’ lections at Tbilisi State Medical University, Lections for students and physicians 1. Urticaria, 2. Angioedema, 3. HIV/AIDS. Tbilisi, Georgia, October 9-12, 2012 39. Magen E. Chronic urticaria can be triggered by eradication of Helicobacter pylori. The 2nd International Allergy, Asthma & Immunology Congress, Jerusalem, November, 2012 40. Magen E. Praxis Research & Consulting Ltd. The management of chronic spontaneous urticaria and the dynamics of the future market, Guildford, United Kingdom November, 2012 41. Magen E. Geriatric medicine in primary care, what a family physician should know. The Community Medicine Regional Congress, Ashkelon, Israel, May, 2013 42. Magen E. Urticaria and angioedema in primary care. The meeting of the Israel Ambulatory Pediatric Association and Leumit Health Services, October 28, Tel Aviv. Israel 2013 43. Magen E. Chronic Opisthorchis felineus Infection Attenuates Atherosclerosis - An Autopsy Study. Israeli Society of Allergy and Clinical Immunology Annual Congress, Israel, November, 2013 32. Magen E. Selective IgE deficiency, respiratory pathology, immune dysregulation and autoimmunity. The Joint International Pulmonology and Clinical Immunology Congress, Batumi, Georgia, June 19-22, 2014 33. Magen E. Chronic helminth infection and immunomodulation of atherosclerosis. Israeli Society of hypertension Annual Congress, Tel Aviv, Israel, March 19-21, 2015 34. Magen E. Expression of toll like receptors TLR2 and TLR4 on peripheral blood monocytes during exacerbation of atopic dermatitis. The Joint World Allergy Organization (WAO) and Georgian Allergy & Clinical Immunology Congress, Tbilisi, Georgia, June 26-29, 2015 35. Magen E. Irritable bowel syndrome responding to Omalizumab. Israeli Society of Allergy and Clinical Immunology Annual Congress, Caesarea, Israel, December 3-5, 2015 36. Magen E. Expression of TLR2 and TLR4 on peripheral blood monocytes during exacerbation of atopic dermatitis. 5th International Congress of Georgian Respiratory Association, 23-25 june, 2016 Batumi, Georgia 37. * Magen E. Possible autoimmune primary ovarian insufficiency in patients with selective IgA deficiency. V European Congress on Asthma & COPD; Tbilisi, Georgia, June 29, 2017 38. * Magen E. Idiopathic angioedema. The European Angioedema Workshop, Berlin, 14-17 April 2018 39. * Magen E. Immune mechanisms of CAR T Cell therapy. International congress in tumor immunology. TSMU, Tbilisi, Georgia. 18 June, 2018. 40. * Magen E. CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers. International meeting in tumor immunology. Geneva, Switzerland, December 2018. 41. * Magen E. Histamin and bradykinin in the pathophysiology of immunological edema. The Mediterranean Angioedema Workshop, Ashkelon 4-6 September 2019 42. * Magen E. Possible autoimmune primary ovarian insufficiency in patients with selective IgA deficiency. Allergy and Clinical Immunology Annual Congress, Kfar Blum, Israel, November, 2019 43. * Magen E. IgE Immunotherapy Against Cancer, the role of Mast cells. University Hospital of Antwerp – UZA. Belgium. February 2019. 44. * Magen E. Long term (> 1 year) treatment of chronic spontaneous urticaria with Omalizumab-A real life study. European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI): ‏ London, England, June, 2020 45. * Magen E. COVID-19 Susceptibility in bronchial Asthma. Allergy and Clinical Immunology Annual Congress, Tel Aviv, Israel, November, 2020 46. * Magen E. Food allergy-exacerbated atypical hidradenitis suppurativa. Allergy and Clinical Immunology Annual Congress, Tel Aviv, Israel, November, 2020 47. * Magen E. Autoimmune Inner Ear Disease among Patients with Selective IgA Deficiency. Allergy and Clinical Immunology Annual Congress, Tel Aviv, Israel, November, 2020 48. * Magen E. Food-dependent exercise-induced angioedema. Allergy and Clinical Immunology Annual Meeting, Tel Aviv, Israel, September, 2021 49. * Magen E. Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression. XI Georgian National Congress of Allergy, Asthma and Immunology, and International School “Molecular Allergology and Vaccination” May 2022, Tbilisi, Georgia 50. * Magen E. Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. VII European Congress on Asthma, COPD and Respiratory Allergy; 8-10 September 2022, Batumi, Georgia 51. * Magen E. New concepts in the diagnosis and management of food allergy. The family medicine education conference in the southern region. 16 October 2022, Beer Sheva, Israel. 52. * Magen E. Histaminergic angioedema and chronic spontaneous urticaria. WAO-BSACI Conference. October 2022, Istanbul, Turkiye 53. * Magen E. Glucose-6-phosphate dehydrogenase deficiency and long-term risk of immune-related disorders. Allergy and Clinical Immunology Meeting, Tel Aviv, Israel, February 2023 54. * Magen E. Type II autoimmunity in chronic spontaneous urticaria. World Allergy Organization (WAO): Skin Allergy-Urticaria & HAE Committee Meeting. April, 2023, Milwaukee, WI, USA 55. * Magen E. A comparative study of chronic spontaneous urticaria and chronic mast cell mediated angioedema. Allergy and Clinical Immunology Annual Meeting, November 2023 Jerusalem, Israel